Myriad Genetics News

Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)

TipRanksMar 6 20:36

Myriad Genetics: Hold Rating Amidst Growth and Market Uncertainty

TipRanksMar 1 14:03

Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)

TipRanksFeb 28 20:32

Myriad Genetics: A Sell Rating Amidst Profitability and Growth Concerns

TipRanksFeb 28 19:57

Myriad Genetics: Hold Rating Maintained Amid Balanced Performance and Cautious Outlook

TipRanksFeb 28 10:55

Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)

TipRanksFeb 8 20:39

Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $31

BenzingaJan 30 21:59

Myriad Genetics Analyst Ratings

BenzingaJan 30 21:58

Myriad Genetics Analyst Ratings

BenzingaJan 29 23:33

BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating

MT NewswiresJan 29 23:32

Myriad Genetics Analyst Ratings

BenzingaDec 21, 2023 18:33

Wells Fargo Initiates Coverage On Myriad Genetics With Equal-Weight Rating, Announces Price Target of $20

BenzingaDec 20, 2023 00:08

Myriad Genetics Analyst Ratings

BenzingaDec 20, 2023 00:07

Guggenheim Initiates Coverage On Myriad Genetics With Buy Rating, Announces Price Target of $23

BenzingaDec 14, 2023 19:36

Myriad Genetics Analyst Ratings

BenzingaDec 14, 2023 00:56

Myriad Genetics: Hold Rating Amid Strong Revenues and Cautious Optimism for Future Growth

TipRanksNov 8, 2023 13:34

Myriad Genetics Analyst Ratings

BenzingaNov 8, 2023 04:14

Goldman Sachs Reaffirms Their Buy Rating on Myriad Genetics (MYGN)

TipRanksNov 7, 2023 22:06

Hold Rating on Myriad Genetics: Balancing Solid Performance With Valuation Concerns

TipRanksNov 7, 2023 13:55

BofA Securities Trims Price Target on Myriad Genetics to $18 From $21, Maintains Underperform Rating

MT NewswiresOct 20, 2023 22:48